{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:30:54Z","timestamp":1792672254760,"version":"4.5.0"},"reference-count":74,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"\n Importance<\/jats:title>\n The involvement of the serotonin system in the pathophysiology of schizophrenia has been proposed for over 60 years, but there has been no prior study to test if there is altered serotonin release in vivo in schizophrenia (to the authors\u2019 knowledge).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate serotonin release in vivo in schizophrenia and its association with negative symptoms. It was hypothesized a priori that frontal cortex serotonin release capacity would be lower in schizophrenia compared with healthy controls and that this would be associated with more severe baseline negative symptoms.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This was a single-center case-control neuroimaging study conducted in London, UK. All participants had dynamic 90-minute [\n 11<\/jats:sup>\n C]Cimbi-36 positron emission tomography (PET) scans at baseline and 3 hours after oral administration of\n d<\/jats:sc>\n -amphetamine 0.5mg\/kg. Data were collected between 2015 and 2024. Participants included stable adult outpatients with\n DSM-5<\/jats:italic>\n schizophrenia (antipsychotic free or taking antipsychotics with negligible affinity for 5-hydroxytryptamine receptor 2A [5-HT2A] receptors) and healthy controls matched for age, sex, and body mass index.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary neuroimaging outcome was the group difference in serotonin release capacity, prespecified as the percentage change in frontal cortex [\n 11<\/jats:sup>\n C]Cimbi-36 binding potential between the baseline and\n d<\/jats:sc>\n -amphetamine scans.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 54 individuals were included, 26 with\n DSM-5<\/jats:italic>\n schizophrenia (mean [SD] age, 33.3 [9.1] years, 16 male [62%]; 21 not taking antipsychotic medication [81%]) and 28 healthy controls (mean [SD] age, 32.0 [9.5] years, 19 male [68%]). Frontal cortex serotonin release was significantly greater in the group with schizophrenia compared with healthy controls (18.0%; 95% CI, 2.5%-33.6%;\n P<\/jats:italic>\n \u2009=\u2009.02; Cohen\n d<\/jats:italic>\n \u2009=\u20090.69). In schizophrenia, greater frontal cortex serotonin release was correlated with more severe baseline negative symptoms (Brief Negative Symptom Scale: Pearson\n r<\/jats:italic>\n \u2009=\u20090.42;\n P<\/jats:italic>\n \u2009=\u2009.04) and poorer functioning (Social Functioning Scale: Pearson\n r<\/jats:italic>\n \u2009=\u2009\u22120.42;\n P<\/jats:italic>\n \u2009=\u2009.04). Exploratory analyses showed significantly greater frontal cortex serotonin release in deficit schizophrenia, characterized by primary and enduring negative symptoms, compared with healthy controls (mean difference\u2009=\u200932.3%; FDR-corrected\n P<\/jats:italic>\n value\u2009=\u20090.001; Cohen\n d<\/jats:italic>\n \u2009=\u20091.10) and nondeficit schizophrenia (mean difference\u2009=\u200928.9%; FDR-corrected\n P<\/jats:italic>\n value\u2009=\u20090.004; Cohen\n d<\/jats:italic>\n \u2009=\u20090.89). These findings were all replicated in 21 individuals with schizophrenia not taking antipsychotic medication. Baseline cortical [\n 11<\/jats:sup>\n C]Cimbi-36 binding (indexing baseline cortical 5-HT2A receptor levels) was unaltered in schizophrenia.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This case-control study found that serotonergic dysfunction in the pathophysiology of schizophrenia was associated with negative symptoms, suggesting the regulation of serotonin release as a target to treat negative symptoms. Results of the exploratory analysis suggest particularly marked serotonergic dysfunction in the subgroup with deficit schizophrenia.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.3430","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:00:27Z","timestamp":1765382427000},"page":"185","source":"Crossref","is-referenced-by-count":10,"title":["Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative Symptoms"],"prefix":"10.1001","volume":"83","author":[{"given":"Martin","family":"Osugo","sequence":"first","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Whitehurst","sequence":"additional","affiliation":[{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London, United Kingdom"},{"name":"Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom"},{"name":"East London NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erritzoe","sequence":"additional","affiliation":[{"name":"Centres for Neuropsychopharmacology and Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishekh H.","family":"Ashok","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London, United Kingdom"},{"name":"Department of Radiology, University of Cambridge, Cambridge, United Kingdom"},{"name":"Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Maccioni","sequence":"additional","affiliation":[{"name":"Department of Information Engineering, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis Chika","family":"Onwordi","sequence":"additional","affiliation":[{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London, United Kingdom"},{"name":"Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom"},{"name":"East London NHS Foundation Trust, London, United Kingdom"},{"name":"Centre for Psychiatry and Mental Health, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Rutigliano","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Rahaman","sequence":"additional","affiliation":[{"name":"Central and North West London NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atheeshaan","family":"Arumuham","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"de Marvao","sequence":"additional","affiliation":[{"name":"Medical Research Council, Laboratory of Medical Sciences, Imperial College London, London, United Kingdom"},{"name":"Department of Women and Children\u2019s Health, King\u2019s College London, London, United Kingdom"},{"name":"British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine and Sciences, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger N.","family":"Gunn","sequence":"additional","affiliation":[{"name":"XingImaging, London, United Kingdom"},{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenii A.","family":"Rabiner","sequence":"additional","affiliation":[{"name":"Perceptive Discovery, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Reis","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Veronese","sequence":"additional","affiliation":[{"name":"Department of Information Engineering, University of Padova, Padova, Italy"},{"name":"Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"yoi250057r1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014An Overview.","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"yoi250057r2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"5","author":"GBD 2016 Alcohol and Drug Use Collaborators","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"yoi250057r3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. a systematic review and meta-analyses.","volume":"13","author":"Moreno-K\u00fcstner","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"yoi250057r4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1192\/bjp.2023.57","article-title":"Treating negative symptoms of schizophrenia: current approaches and future perspectives.","volume":"223","author":"Howes","year":"2023","journal-title":"Br J Psychiatry"},{"issue":"8","key":"yoi250057r5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions.","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"41","key":"yoi250057r6","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0602-24.2024","article-title":"Striatal serotonin release signals reward value.","volume":"44","author":"Spring","year":"2024","journal-title":"J Neurosci"},{"issue":"1","key":"yoi250057r7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1460-9568.2010.07480.x","article-title":"Activation of the central serotonergic system in response to delayed but not omitted rewards.","volume":"33","author":"Miyazaki","year":"2011","journal-title":"Eur J Neurosci"},{"issue":"11","key":"yoi250057r8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048975","article-title":"Mice genetically depleted of brain serotonin display social impairments, communication deficits, and repetitive behaviors: possible relevance to autism.","volume":"7","author":"Kane","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"yoi250057r9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13229-015-0003-6","article-title":"Reduced isolation-induced pup ultrasonic communication in mouse pups lacking brain serotonin.","volume":"6","author":"Mosienko","year":"2015","journal-title":"Mol Autism"},{"issue":"2","key":"yoi250057r10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41380-024-02696-1","article-title":"Dynamics of human serotonin synthesis differentially link to reward anticipation and feedback.","volume":"30","author":"Hahn","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"4","key":"yoi250057r11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials.","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr Bull"},{"issue":"1","key":"yoi250057r12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000119323","article-title":"Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms.","volume":"35","author":"Sharma","year":"1997","journal-title":"Neuropsychobiology"},{"issue":"10","key":"yoi250057r13","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/sj.npp.1301656","article-title":"Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients.","volume":"33","author":"Erritzoe","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yoi250057r14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archgenpsychiatry.2009.176","article-title":"Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia.","volume":"67","author":"Rasmussen","year":"2010","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"yoi250057r15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41398-021-01430-7","article-title":"Opposite alterations of 5-HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile.","volume":"11","author":"Diez-Alarcia","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"5","key":"yoi250057r16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41386-019-0567-5","article-title":"Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge.","volume":"45","author":"Erritzoe","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"yoi250057r17","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/j.1471-4159.1984.tb05375.x","article-title":"Guanyl nucleotide and divalent cation regulation of cortical S2 serotonin receptors.","volume":"43","author":"Battaglia","year":"1984","journal-title":"J Neurochem"},{"issue":"2","key":"yoi250057r18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0165-1781(89)90153-4","article-title":"The schedule for the deficit syndrome: an instrument for research in schizophrenia.","volume":"30","author":"Kirkpatrick","year":"1989","journal-title":"Psychiatry Res"},{"issue":"4","key":"yoi250057r19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/schbul\/sbx064","article-title":"Primary, enduring negative symptoms: an update on research.","volume":"43","author":"Kirkpatrick","year":"2017","journal-title":"Schizophr Bull"},{"issue":"9596","key":"yoi250057r20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"yoi250057r21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0197-4580(02)00137-9","article-title":"Imaging of the 5-HT2A system: age-, gender-, and Alzheimer disease-related findings.","volume":"24","author":"Versijpt","year":"2003","journal-title":"Neurobiol Aging"},{"issue":"1","key":"yoi250057r22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pscychresns.2009.08.007","article-title":"Gender, personality, and serotonin-2A receptor binding in healthy subjects.","volume":"181","author":"Soloff","year":"2010","journal-title":"Psychiatry Res"},{"issue":"1","key":"yoi250057r23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuroimage.2009.01.050","article-title":"Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use.","volume":"46","author":"Erritzoe","year":"2009","journal-title":"Neuroimage"},{"issue":"12","key":"yoi250057r24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.biopsych.2022.10.012","article-title":"Brain Serotonin release is reduced in patients with depression: a [11C]Cimbi-36 positron emission tomography study with a d-amphetamine challenge.","volume":"93","author":"Erritzoe","year":"2023","journal-title":"Biol Psychiatry"},{"issue":"9","key":"yoi250057r25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/15622975.2024.2366235","article-title":"Optimization of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging, and pharmacogenetic tests: focus on antipsychotics.","volume":"25","author":"Hart","year":"2024","journal-title":"World J Biol Psychiatry"},{"key":"yoi250057r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104568","article-title":"Dopamine partial agonists and prodopaminergic drugs for schizophrenia: systematic review and meta-analysis of randomized controlled trials.","volume":"135","author":"Osugo","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"yoi250057r27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hup.480","article-title":"Relationship of plasma amphetamine levels to physiological, subjective, cognitive, and biochemical measures in healthy volunteers.","volume":"18","author":"Asghar","year":"2003","journal-title":"Hum Psychopharmacol"},{"issue":"8","key":"yoi250057r28","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1038\/s41380-022-01596-6","article-title":"The relationship between glutamate, dopamine, and cortical gray matter: a simultaneous PET-MR study.","volume":"27","author":"Rogeau","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"24","key":"yoi250057r29","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg1512","article-title":"Dopaminergic organization of striatum is linked to cortical activity and brain expression of genes associated with psychiatric illness.","volume":"7","author":"McCutcheon","year":"2021","journal-title":"Sci Adv"},{"issue":"2","key":"yoi250057r30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"2","key":"yoi250057r31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties.","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr Bull"},{"key":"yoi250057r32","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1192\/bjp.157.6.853","article-title":"The Social Functioning Scale\u2014The development and validation of a new scale of social adjustment for use in family intervention programs with schizophrenic patients.","volume":"157","author":"Birchwood","year":"1990","journal-title":"Br J Psychiatry"},{"key":"yoi250057r33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2014.06.005","article-title":"Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies.","volume":"45","author":"Selvaraj","year":"2014","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"yoi250057r34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1098-2396(20001215)38:4<421::AID-SYN7>3.0.CO;2-X","article-title":"Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907.","volume":"38","author":"Hall","year":"2000","journal-title":"Synapse"},{"issue":"7","key":"yoi250057r35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jcbfm.2014.68","article-title":"Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36.","volume":"34","author":"Ettrup","year":"2014","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"yoi250057r36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.neuroimage.2010.06.044","article-title":"Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy.","volume":"54","author":"Tziortzi","year":"2011","journal-title":"Neuroimage"},{"issue":"9","key":"yoi250057r37","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","article-title":"Consensus nomenclature for in vivo imaging of reversibly binding radioligands.","volume":"27","author":"Innis","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"issue":"10","key":"yoi250057r38","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/01.WCB.0000038000.34930.4E","article-title":"Strategies to improve neuroreceptor parameter estimation by linear regression analysis.","volume":"22","author":"Ichise","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"yoi250057r39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamapsychiatry.2022.4539","article-title":"Serotonin 4 receptor brain binding in major depressive disorder and association with memory dysfunction.","volume":"80","author":"K\u00f6hler-Forsberg","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"yoi250057r40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1192\/bjp.2024.143","article-title":"Consistent evidence that brain serotonin 2A receptor binding is positively associated with personality-based risk markers of depression.","volume":"226","author":"H\u00f8gsted","year":"2025","journal-title":"Br J Psychiatry"},{"key":"yoi250057r41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2023.06.023","article-title":"The association between brain serotonin transporter binding and impulsivity and aggression in healthy individuals.","volume":"165","author":"da Cunha-Bang","year":"2023","journal-title":"J Psychiatr Res"},{"key":"yoi250057r42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pscychresns.2018.04.002","article-title":"Higher 5-HT1A autoreceptor binding as an endophenotype for major depressive disorder identified in high risk offspring\u2014A pilot study.","volume":"276","author":"Milak","year":"2018","journal-title":"Psychiatry Res Neuroimaging"},{"issue":"1","key":"yoi250057r43","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41467-025-56663-7","article-title":"Striatal dopamine D2\/D3 receptor regulation of human reward processing and behavior.","volume":"16","author":"Osugo","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"yoi250057r44","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41386-025-02120-4","article-title":"Antipsychotics cause reversible structural brain changes within 1 week.","volume":"50","author":"Selvaggi","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"yoi250057r45","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1038\/s41380-025-03116-8","article-title":"Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2\/D3 antagonism, D2\/D3 partial agonism, and placebo.","volume":"30","author":"Osugo","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"1","key":"yoi250057r46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"issue":"1","key":"yoi250057r47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5334\/joc.10","article-title":"Power analysis and effect size in mixed effects models: a tutorial.","volume":"1","author":"Brysbaert","year":"2018","journal-title":"J Cogn"},{"issue":"3","key":"yoi250057r48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-007-0791-2","article-title":"Dissociating effects of cocaine and d-amphetamine on dopamine and serotonin in the perirhinal, entorhinal, and prefrontal cortex of freely moving rats.","volume":"193","author":"Pum","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"yoi250057r49","first-page":"440","article-title":"Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.","volume":"178","author":"Toll","year":"1998","journal-title":"NIDA Res Monogr"},{"issue":"10","key":"yoi250057r50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/syn.21835","article-title":"Optimizing PET approaches to measuring 5-HT release in human brain.","volume":"69","author":"Tyacke","year":"2015","journal-title":"Synapse"},{"issue":"4","key":"yoi250057r51","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00259-010-1686-8","article-title":"Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers.","volume":"38","author":"Ettrup","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"yoi250057r52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/0271678X16629483","article-title":"Cerebral 5-HT release correlates with [11C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain.","volume":"37","author":"J\u00f8rgensen","year":"2017","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"yoi250057r53","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1503\/jpn.120209","article-title":"Acute tryptophan depletion in humans: a review of theoretical, practical, and ethical aspects.","volume":"38","author":"Young","year":"2013","journal-title":"J Psychiatry Neurosci"},{"issue":"2","key":"yoi250057r54","first-page":"119","article-title":"Evaluating the effect of melatonin on positive and negative symptoms of schizophrenic patients: a randomized placebo-controlled study.","volume":"18","author":"Behrouzian","year":"2023","journal-title":"Iran J Psychiatry"},{"issue":"8","key":"yoi250057r55","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1176\/ajp.108.8.572","article-title":"Experimental schizophrenia-like symptoms.","volume":"108","author":"Rinkel","year":"1952","journal-title":"Am J Psychiatry"},{"issue":"17","key":"yoi250057r56","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"issue":"3","key":"yoi250057r57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation.","volume":"27","author":"Preller","year":"2017","journal-title":"Curr Biol"},{"issue":"8","key":"yoi250057r58","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","article-title":"Acute effects of lysergic acid diethylamide in healthy subjects.","volume":"78","author":"Schmid","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"4","key":"yoi250057r59","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1098-2396(199704)25:4<321::AID-SYN2>3.0.CO;2-C","article-title":"Effect of reserpine-induced depletion of synaptic dopamine on [11C]raclopride binding to D2-dopamine receptors in the monkey brain.","volume":"25","author":"Ginovart","year":"1997","journal-title":"Synapse"},{"issue":"1","key":"yoi250057r60","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s42003-022-03690-5","article-title":"Serotonin modulates asymmetric learning from reward and punishment in healthy human volunteers.","volume":"5","author":"Michely","year":"2022","journal-title":"Commun Biol"},{"issue":"48","key":"yoi250057r61","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc7246","article-title":"Serotonergic projections to the orbitofrontal and medial prefrontal cortices differentially modulate waiting for future rewards.","volume":"6","author":"Miyazaki","year":"2020","journal-title":"Sci Adv"},{"issue":"8064","key":"yoi250057r62","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41586-025-08731-7","article-title":"A prospective code for value in the serotonin system.","volume":"641","author":"Harkin","year":"2025","journal-title":"Nature"},{"issue":"26","key":"yoi250057r63","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ads1236","article-title":"Dorsal raphe nucleus controls motivation-state transitions in monkeys.","volume":"11","author":"Priestley","year":"2025","journal-title":"Sci Adv"},{"issue":"2","key":"yoi250057r64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/schbul\/17.2.263","article-title":"The mechanism of action of novel antipsychotic drugs.","volume":"17","author":"Meltzer","year":"1991","journal-title":"Schizophr Bull"},{"issue":"3","key":"yoi250057r65","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/sbac013","article-title":"Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia.","volume":"48","author":"Davidson","year":"2022","journal-title":"Schizophr Bull"},{"issue":"1","key":"yoi250057r66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","article-title":"Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomized, placebo-controlled trial in North America and Europe.","volume":"9","author":"Bugarski-Kirola","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi250057r67","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgac006","article-title":"ENHANCE: phase 3, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin for schizophrenia in patients with an inadequate response to antipsychotic treatment.","volume":"3","author":"Bugarski-Kirola","year":"2022","journal-title":"Schizophr Bull Open"},{"issue":"4","key":"yoi250057r68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study.","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"yoi250057r69","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamapsychiatry.2017.2943","article-title":"A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia.","volume":"74","author":"Jauhar","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"yoi250057r70","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi250057r71","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/schbul\/sby076","article-title":"Impaired prefrontal cortical dopamine release in schizophrenia during a cognitive task: a [11C]FLB 457 positron emission tomography study.","volume":"45","author":"Rao","year":"2019","journal-title":"Schizophr Bull"},{"issue":"7","key":"yoi250057r72","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.biopsych.2023.05.022","article-title":"Synaptic terminal density early in the course of schizophrenia: an in vivo UCB-J positron emission tomographic imaging study of SV2A.","volume":"95","author":"Onwordi","year":"2024","journal-title":"Biol Psychiatry"},{"issue":"1","key":"yoi250057r73","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41398-025-03269-8","article-title":"The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging study.","volume":"15","author":"Onwordi","year":"2025","journal-title":"Transl Psychiatry"},{"key":"yoi250057r74","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neubiorev.2020.10.001","article-title":"Proton magnetic resonance spectroscopy of N-acetyl aspartate in chronic schizophrenia, first episode of psychosis and high-risk of psychosis: a systematic review and meta-analysis.","volume":"119","author":"Whitehurst","year":"2020","journal-title":"Neurosci Biobehav Rev"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2842666\/jamapsychiatry_osugo_2025_oi_250057_1768943477.48847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:00:32Z","timestamp":1770220832000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2842666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.3430","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}